New discovery by EU-funded researchers could lead to improved treatment of allergies and asthma

---

Omschrijving
Researchers working in two EU-funded research projects have unravelled the structure of a key enzyme that can trigger allergies and asthma. This breakthrough opens up the possibility of the development of new drugs for treating these and other conditions which are tailor-made for patients, making them more effective. The enzyme, termed LTC4 synthase, is part of the complex process that leads to the production of leukotrienes, which cause allergic symptoms, and motors the inflammatory reaction which causes asthma attacks. Some existing medicines block the effect of this enzyme, but only after the process has taken place. Thanks to these latest findings, published today in the leading scientific magazine Nature, scientists will now be able to tailor new molecules that block LTC4 before it can act. The two projects, named EICOSANOX and E-MeP, are headed by professors from Karolinska Institutet in Stockholm, and one, EICOSANOX, has one Nobel-Prize winning scientist in its team. Together, the two projects received EUR 20 million funding from the EU's Sixth Research Framework Programme.

 

[ Ga naar het volledige artikel toe ]

Categorie: allergie - astma

[Reinig uw lichaam met de Chlorella alg - 100% plantaardig ]

Het hoofdmenu
Nieuws
Supervoeding
Zoek op onderwerp